Acute urate nephropathy

Summary

Acute urate nephropathy (MONDO:0003652) is a disease and 1 clinical trial. Top therapeutic interventions include iodofiltic acid i 123 and technetium tc 99m tiatide. A subtype of nephrolithiasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute urate nephropathy
Mondo ID	MONDO:0003652
DOID	DOID:580
ICD-11	1011901523
NCIT	C123037
SNOMED CT	236496000
UMLS	C0341712
MedGen	574593
Is cancer (heuristic)	no

Also known as: uric acid nephrolithiasis · uric acid urolithiasis

Disease family

This is a subtype of nephrolithiasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephrolithiasis › acute urate nephropathy

Related subtypes (2): nephrolithiasis, X-linked recessive, with renal failure, nephrolithiasis, calcium oxalate

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02975986	Not specified	WITHDRAWN	Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
IODOFILTIC ACID I 123	2	1
TECHNETIUM TC 99M TIATIDE	-1	1